journal
https://read.qxmd.com/read/37732632/activation-of-pi3k-akt-pathway-by-g-protein-coupled-receptor-37-promotes-resistance-to-cisplatin-induced-apoptosis-in-non-small-cell-lung-cancer
#1
JOURNAL ARTICLE
Han Liu, Yingjie Zhu, Huikun Niu, Jing Jie, Shucheng Hua, Xiaoxue Bai, Shuai Wang, Lei Song
OBJECTIVES: Lung cancer is a major public health concern and represents the most common cause of cancer-related death worldwide. Among eukaryotes, the G protein-coupled receptor (GPCR) family stands as the largest group of membrane proteins. Alterations in GPCR gene expression and dysregulation of signal transduction have been recognized as the markers of malignancy. As a member of the GPCR family, G protein-coupled receptor 37 (GPR37) exhibits unknown functions in tumors, particularly in non-small-cell lung cancer (NSCLC) METHODS: We explored the expression and prognosis of GPR37 in NSCLC through TCGA, GTEx, GEO, and GEPIA2...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732511/immunohistochemical-expression-of-nrf2-is-correlated-with-the-magnitude-of-inflammation-and-fibrosis-in-chronic-liver-disease
#2
JOURNAL ARTICLE
Keii To, Kosuke Okada, Takahisa Watahiki, Hideo Suzuki, Kiichiro Tsuchiya, Katsutoshi Tokushige, Masakazu Yamamoto, Shun-Ichi Ariizumi, Junichi Shoda
BACKGROUND: The nuclear factor E2-related factor 2-Kelch-like Ech-associated protein (NRF2-KEAP1) pathway is a major cellular defense mechanism against oxidative stress. However, the role of NRF2-KEAP1 signaling in the development of chronic liver disease remains unclear. METHODS: Clinical liver specimens from 50 hepatocellular carcinoma (HCC) developed from non-alcoholic steatohepatitis (NASH), 49 HCCs developed from chronic viral hepatitis C (CHc), and 48 liver metastases of colorectal cancer (CRC) from both tumorous and non-tumorous areas were collected during hepatic resection surgery...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732496/how-should-extra-large-lugol-unstained-lesions-of-the-esophagus-be-treated-results-from-a-population-based-cohort-study
#3
JOURNAL ARTICLE
Mengfei Liu, Zifan Qi, Ren Zhou, Chuanhai Guo, Anxiang Liu, Haijun Yang, Fenglei Li, Liping Duan, Lin Shen, Qi Wu, Zhen Liu, Yaqi Pan, Fangfang Liu, Ying Liu, Hong Cai, Zhonghu He, Yang Ke
BACKGROUND: Current guidelines recommend only severe dysplasia and above (SDA) lesions of the esophageal squamous epithelium for clinical intervention. However, the histopathologic diagnosis derived from tissue biopsies may be subject to underestimation of severity. METHODS: 1073 participants from whom biopsies were taken at baseline chromoendoscopic examination in a population-based screening trial were enrolled in this study. The size of the Lugol-unstained lesions (LULs) was mainly analyzed...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732493/perspectives-for-immunotherapy-of-ebv-associated-glelc-a-relatively-hot-tumor-microenvironment
#4
JOURNAL ARTICLE
Yanna Lei, Peng Cao, Xiufeng Zheng, Jing Wei, Mo Cheng, Ming Liu
BACKGROUND: Epstein-Barr virus (EBV)-associated gastric lymphoepithelioma-like carcinoma (EBVaGLELC) represents a small number of gastric cancer (GC), and research on tumor microenvironment (TME) and treatment strategy are still lacking. AIMS: Here, we aim to elucidate the immune features of this rare disease and further help to develop more effective treatment options. MATERIALS & METHODS: A retrospective analysis was conducted between 2019 to 2022 in West China Hospital to reveal the immunological characteristics of EBV-positive GLELC...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732488/comparison-of-the-slow-pull-and-aspiration-methods-of-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-for-next-generation-sequencing-compatible-tissue-collection-in-non-small-cell-lung-cancer
#5
JOURNAL ARTICLE
Yukihito Kajita, Shuhei Teranishi, Tomoe Sawazumi, Haruka Watanabe, Satoshi Nagaoka, Anna Tanaka, Yuichirou Suzukawa, Yuto Motobayashi, Tomofumi Hirose, Chihiro Maeda, Kenichi Seki, Ken Tashiro, Nobuaki Kobayashi, Masaki Yamamoto, Makoto Kudo, Yoshiaki Inayama, Takeshi Kaneko
BACKGROUND: Personalized treatment for non-small cell lung cancer (NSCLC) has advanced rapidly, and elucidating the genetic changes that trigger this disease is crucial for appropriate treatment selection. Both slow-pull and aspiration methods of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are accepted methods for collecting samples suitable for next-generation sequencing (NGS) to examine driver gene mutations and translocations in NSCLC. Here, we aimed to determine which of these two methods is superior for obtaining higher-quality samples from patients with NSCLC...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732486/randomized-controlled-trial-on-the-effect-of-1-hour-infusion-of-vincristine-versus-push-injection-on-neuropathy-in-children-with-cancer-final-analysis
#6
JOURNAL ARTICLE
Aniek Uittenboogaard, Marleen H van den Berg, Floor C H Abbink, Jos W R Twisk, Inge M van der Sluis, Cor van den Bos, Marry M van den Heuvel-Eibrink, Heidi Segers, Christophe Chantrain, Jutte van der Werff Ten Bosch, Leen Willems, Gertjan J L Kaspers, Mirjam Esther van de Velde
INTRODUCTION: Vincristine is an integral component of treatment for children with cancer. Its main dose-limiting side effect is vincristine-induced peripheral neuropathy (VIPN). The VINCA trial was a randomized controlled trial that explored the effect of 1-hour infusion compared with push injection of vincristine on the development of VIPN in children with cancer. The short-term outcomes (median follow-up 9 months) showed that there was no difference in VIPN between the randomization groups...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732470/barriers-facilitators-and-recommendations-for-sexual-orientation-and-gender-identity-data-collection-in-community-oncology-practices
#7
JOURNAL ARTICLE
Megan A Mullins, Lisa Reber, Ariel Washington, Marina Stasenko, Aaron Rankin, Christopher R Friese, Mary E Cooley, Matthew F Hudson, Lauren P Wallner
BACKGROUND: Sexual orientation and gender identity (SOGI) data collection in community oncology practices is critical to identify and address cancer inequities, but less than 20% of NCI Community Oncology Research Program (NCORP)-affiliated practices regularly collect SOGI data despite widespread recommendations. We evaluated multilevel barriers and facilitators for SOGI data collection at NCORP practices. METHODS: We conducted 14 semi-structured interviews at seven purposefully sampled NCORP oncology practices...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37732468/cardiorespiratory-fitness-and-bmi-measured-in-youth-and-5-year-mortality-after-site-specific-cancer-diagnoses-in-men-a-population-based-cohort-study-with-register-linkage
#8
JOURNAL ARTICLE
Aron Onerup, Kirsten Mehlig, Elin Ekblom-Bak, Lauren Lissner, Mats Börjesson, Maria Åberg
BACKGROUND: Our aim was to assess associations between cardiorespiratory fitness (CRF) and body mass index (BMI) in youth and 5-year mortality after site-specific cancer diagnoses in men. METHODS: Men with cancer from a population who underwent military conscription at ages 16-25 during 1968-2005 in Sweden were included. CRF was assessed as maximal aerobic workload on a cycle ergometer test and was classified as low, moderate, or high. BMI (kg/m2 ) was classified as underweight (<18...
September 21, 2023: Cancer Medicine
https://read.qxmd.com/read/37724781/retraction
#9
(no author information available yet)
Zhang Z, Tan X, Luo J, Cui B, Lei S, Si Z, Shen L, Yao H. GNA13 promotes tumor growth and angiogenesis by upregulating CXC chemokines via the NF-κB signaling pathway in colorectal cancer cells. Cancer Med. 2018;7(11):5611-5620. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1783. The above article, published online on September 28, 2018, in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal's Editor-in-Chief, Dr Stephen Tait, and John Wiley & Sons Ltd...
September 19, 2023: Cancer Medicine
https://read.qxmd.com/read/37724617/ten-year-work-burden-after-prostate-cancer-treatment
#10
JOURNAL ARTICLE
Samuel L Washington, Peter E Lonergan, Janet E Cowan, Shoujun Zhao, Jeanette M Broering, Nynikka R Palmer, Cameron Hicks, Matthew R Cooperberg, Peter R Carroll
INTRODUCTION: We aim to characterize the magnitude of the work burden (weeks off from work) associated with prostate cancer (PCa) treatment over a 10-year period after PCa diagnosis and identify those at greatest risk. MATERIALS AND METHODS: We identified men diagnosed with PCa treated with radical prostatectomy, radiation therapy, or active surveillance/watchful waiting within CaPSURE. Patients self-reported work burden and SF36 general health scores via surveys before and 1,3,5, and 10 years after treatment...
September 19, 2023: Cancer Medicine
https://read.qxmd.com/read/37724607/real-world-experience-of-tyrosine-kinase-inhibitors-in-children-adolescents-and-adults-with-relapsed-or-refractory-bone-tumours-a-canadian-sarcoma-research-and-clinical-collaboration-cansarcc-study
#11
JOURNAL ARTICLE
Hagit Peretz Soroka, Tushar Vora, Jonathan Noujaim, Nicolas Marcoux, Sarah Cohen-Gogo, Thierry Alcindor, Caroline Holloway, Caroline Rodrigues, Hatim Karachiwala, Saima Alvi, Ursula Lee, Sylvia Cheng, Shantanu Banerji, Sapna Oberoi, Xiaolan Feng, Alannah Smrke, Christine Simmons, Albiruni Abdul Razak, Abha A Gupta
OBJECTIVES: We conducted a retrospective multi-centre study to assess the real-world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) and chondrosarcoma (CS)/extra-skeletal mesenchymal CS (ESMC). METHODS: After regulatory approval, data from patients with recurrent BT (11 institutions) were extracted from CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) database...
September 19, 2023: Cancer Medicine
https://read.qxmd.com/read/37724594/analysis-on-the-risk-of-myasthenia-gravis-related-to-immune-checkpoint-inhibitors-based-on-the-us-fda-adverse-event-reporting-system
#12
JOURNAL ARTICLE
Qingli Kong, Hui Wang, Xiaolei Ren, Yue Zhuo, Jing Peng
OBJECTIVE: To evaluate the risk of myasthenia gravis (MG) associated with immune checkpoint inhibitors (ICI). METHODS: Adverse event (AE) reports related to MG, myasthenic syndrome, and MG crisis for durvalumab, atezolizumab, pembrolizumab, nivolumab, avelumab, and ipilimumab in the US FDA Adverse Event Reporting System (FAERS) from Q1 2004 to Q3 2022 were collected. The proportional reporting odds ratio (PRR) method was used to evaluate the correlation between the six drugs and the three AEs...
September 19, 2023: Cancer Medicine
https://read.qxmd.com/read/37724570/elderly-nasopharyngeal-carcinoma-patients-aged-%C3%A2-70%C3%A2-years-survival-and-treatment-strategies
#13
JOURNAL ARTICLE
Gang Yang, Jingjing Huang, Ji Sun, Li Wang
BACKGROUND: With the coming of the aging society, the incidence of elderly nasopharyngeal carcinoma (NPC) has been increasing which may result in considerable disease burden; however, the optimal treatment strategy for elderly patients is still debatable. METHODS AND RESULTS: Clinical data on 294 elderly NPC patients aged ≥70 treated between 2009 and 2019 was analyzed. Kaplan-Meier method was used to estimate overall survival (OS) and cancer-specific survival (CSS) rates...
September 19, 2023: Cancer Medicine
https://read.qxmd.com/read/37723872/discrimination-of-ground-glass-nodular-lung-adenocarcinoma-pathological-subtypes-via-transfer-learning-a-multicenter-study
#14
JOURNAL ARTICLE
Chun-Long Fu, Ze-Bin Yang, Ping Li, Kang-Fei Shan, Mei-Kang Wu, Jie-Ping Xu, Chi-Jun Ma, Fang-Hong Luo, Long Zhou, Ji-Hong Sun, Fen-Hua Zhao
BACKGROUND: The surgical approach and prognosis for invasive adenocarcinoma (IAC) and minimally invasive adenocarcinoma (MIA) of the lung differ. However, they both manifest as identical ground-glass nodules (GGNs) in computed tomography images, and no effective method exists to discriminate them. METHODS: We developed and validated a three-dimensional (3D) deep transfer learning model to discriminate IAC from MIA based on CT images of GGNs. This model uses a 3D medical image pre-training model (MedicalNet) and a fusion model to build a classification network...
September 18, 2023: Cancer Medicine
https://read.qxmd.com/read/37723846/the-efficacy-and-safety-of-chemo-free-therapy-in-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-resistant-advanced-non-small-cell-lung-cancer-a-single-arm-phase-ii-study
#15
JOURNAL ARTICLE
Shuyang Zhang, Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wang
OBJECTIVES: The purpose of this study was to explore the efficacy and safety of toripalimab combined with anlotinib in patients with advanced non-small cell lung cancer (NSCLC) who acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). MATERIALS AND METHODS: Patients who developed resistance after using first- or second-generation EGFR-TKIs as their first-line regimen without EGFR T790M mutation or had disease progression after being treated with third-generation EGFR-TKIs as first- or second-line therapy were enrolled...
September 18, 2023: Cancer Medicine
https://read.qxmd.com/read/37723837/sintilimab-plus-anlotinib-as-second-or-third-line-therapy-in-metastatic-non-small-cell-lung-cancer-with-uncommon-epidermal-growth-factor-receptor-mutations-a-prospective-single-arm-phase-ii-trial
#16
JOURNAL ARTICLE
Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
BACKGROUND: Patients with non-small-cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR-mutated NSCLC. This study aimed to investigate the efficacy and safety of PD-1 blockade with sintilimab plus anti-angiogenic treatment with anlotinib in patients with NSCLC harboring uncommon EGFR mutations. METHODS: Patients with metastatic NSCLC harboring uncommon EGFR mutations after two previous treatments, including a platinum-based chemotherapy regimen and a targeted treatment (or chemotherapy only for patients harboring EGFR ex20ins), received sintilimab combined with anlotinib...
September 18, 2023: Cancer Medicine
https://read.qxmd.com/read/37723836/depression-and-anxiety-in-cancer-patient-enrolled-in-clinical-trials-with-serious-adverse-events
#17
JOURNAL ARTICLE
Zhen Peng, Chongwei Wang, Yubei Sun, Yan Ma, Jumei Wang, Fei Xu, Xiaoling Xu, Yin Chen
OBJECTIVE: Drug-induced side effects, particularly serious adverse events (SAEs), often affect cancer patients enrolled in clinical trials. However, little is known about anxiety and depression in cancer patients who experienced SAEs. This study evaluated the prevalence of anxiety and depression in cancer patients enrolled in clinical trials who experienced SAEs and explored the risk factors. METHODS: A multi-center, cross-sectional survey was conducted in hospitals affiliated with the University of Science and Technology of China from December 2021 to November 2022...
September 18, 2023: Cancer Medicine
https://read.qxmd.com/read/37712718/cancer-treatment-delays-among-cancer-patients-living-with-hiv-during-the-covid-19-pandemic-in-the-united-states
#18
JOURNAL ARTICLE
Ashley Khouri, Jessica Y Islam, Nathan W Van Bibber, Anna E Coghill, Gita Suneja
BACKGROUND: The COVID-19 pandemic led to care disruptions across the cancer continuum. It is unknown if immunosuppressed patients with cancer, who may be at higher risk for complications of SARS-CoV-2 infection, are disproportionately impacted. Thus, we aimed to compare delays in cancer treatment initiation between people living with HIV (PLWH) and cancer, the general cancer population (GCP), and patients with cancer and a history of solid organ transplant (SOT). Comparisons were made across the period 2 years preceding the pandemic versus the first year of the pandemic...
September 15, 2023: Cancer Medicine
https://read.qxmd.com/read/37712717/the-possibility-of-mutations-of-ras-signaling-genes-and-or-tp53-in-combination-as-a-negative-prognostic-impact-on-pathological-stage-i-non-small-cell-lung-cancer
#19
JOURNAL ARTICLE
Takayuki Honda, Katsutoshi Seto, Satoshi Endo, Akira Takemoto, Kousuke Tanimoto, Masashi Kobayashi, Masatake Kitano, Rie Sakakibara, Takahiro Mitsumura, Hironori Ishibashi, Johji Inazawa, Toshihiro Tanaka, Yasunari Miyazaki, Kenichi Okubo
BACKGROUND: The recurrence rate of non-small cell lung cancer (NSCLC) is as high as 30%, even in the cancer with pathological stage I disease. Therefore, identifying factors predictive of high-risk pathological recurrence is important. However, few studies have examined the genetic status of these tumors and its relationship to prognosis. MATERIALS AND METHODS: A cohort of 328 cases of primary lung cancer that underwent complete resection at Tokyo Medical and Dental University (TMDU) was screened for 440 cancer-associated genes using panel testing...
September 15, 2023: Cancer Medicine
https://read.qxmd.com/read/37712677/assessing-the-utility-of-molecular-diagnostic-classification-for-cancers-of-unknown-primary
#20
JOURNAL ARTICLE
Elle C Moore, Gerard C Blobe, Nicholas C DeVito, Brent A Hanks, Michael R Harrison, Christopher J Hoimes, Jingquan Jia, Michael A Morse, Parvathy Jayaprakasan, Andrew MacKelfresh, Hillary Mulder, Adam J Hockenberry, Alia Zander, Martin C Stumpe, Jackson Michuda, Kyle A Beauchamp, Eric Perakslis, Timothy Taxter, Daniel J George
BACKGROUND: Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with regard to clinical impact. In this retrospective study, we evaluated the utility of a novel molecular diagnostic classifier by assessing theoretical changes in treatment and additional testing recommendations from oncologists before and after the review of classifier predictions...
September 15, 2023: Cancer Medicine
journal
journal
44165
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.